Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Olfson

Showing results (71-80 of 683) with videos related to

Pageof 69
Sort By:
Drug and Alcohol Dependence Reports|January 16, 2023
Gaps and barriers in drug and alcohol treatment following implementation of the affordable care actCatherine Tomko, Mark Olfson, Ramin Mojtabai
Journal of Clinical Epidemiology|July 16, 2013
The use of clinical trials in comparative effectiveness research on mental healthCarlos Blanco, Claudia Rafful, Mark Olfson
JAMA Psychiatry|December 18, 2014
Benzodiazepine use in the United StatesMark Olfson, Marissa King, Michael Schoenbaum
The American Journal of Psychiatry|December 2, 2017
Facilitating Temporary, Safe Firearms Restrictions Among Individuals at High Risk of Suicide: Response to SungMark Olfson, Stephen Crystal, Tobias Gerhard
Journal of Child and Adolescent Psychopharmacology|March 17, 2016
Stimulant Treatment of Young People in the United StatesMark Olfson, Marissa King, Michael Schoenbaum
JAMA Psychiatry|September 10, 2025
National Trends in Inpatient Psychiatric Bed Supply, 2011 to 2023Karen Shen, Mark Olfson, Adam Sacarny
JAMA Psychiatry|July 2, 2015
Treatment of Young People With Antipsychotic Medications in the United StatesMark Olfson, Marissa King, Michael Schoenbaum
Journal of the American Academy of Child and Adolescent Psychiatry|February 17, 2009
Stimulant dosing for children with ADHD: a medical claims analysisMark Olfson, Steven Marcus, George Wan
Pediatrics|December 13, 2016
National Trends in the Prevalence and Treatment of Depression in Adolescents and Young AdultsRamin Mojtabai, Mark Olfson, Beth Han
JAMA Psychiatry|April 2, 2015
The popularity of benzodiazepines, their advantages, and inadequate pharmacological alternatives-replyMark Olfson, Marissa King, Michael Schoenbaum
Pageof 69

Showing results (71-80 of 683) with videos related to

Sort By:
Pageof 69
Drug and Alcohol Dependence Reports|January 16, 2023
Gaps and barriers in drug and alcohol treatment following implementation of the affordable care actCatherine Tomko, Mark Olfson, Ramin Mojtabai
Journal of Clinical Epidemiology|July 16, 2013
The use of clinical trials in comparative effectiveness research on mental healthCarlos Blanco, Claudia Rafful, Mark Olfson
JAMA Psychiatry|December 18, 2014
Benzodiazepine use in the United StatesMark Olfson, Marissa King, Michael Schoenbaum
The American Journal of Psychiatry|December 2, 2017
Facilitating Temporary, Safe Firearms Restrictions Among Individuals at High Risk of Suicide: Response to SungMark Olfson, Stephen Crystal, Tobias Gerhard
Journal of Child and Adolescent Psychopharmacology|March 17, 2016
Stimulant Treatment of Young People in the United StatesMark Olfson, Marissa King, Michael Schoenbaum
JAMA Psychiatry|September 10, 2025
National Trends in Inpatient Psychiatric Bed Supply, 2011 to 2023Karen Shen, Mark Olfson, Adam Sacarny
JAMA Psychiatry|July 2, 2015
Treatment of Young People With Antipsychotic Medications in the United StatesMark Olfson, Marissa King, Michael Schoenbaum
Journal of the American Academy of Child and Adolescent Psychiatry|February 17, 2009
Stimulant dosing for children with ADHD: a medical claims analysisMark Olfson, Steven Marcus, George Wan
Pediatrics|December 13, 2016
National Trends in the Prevalence and Treatment of Depression in Adolescents and Young AdultsRamin Mojtabai, Mark Olfson, Beth Han
JAMA Psychiatry|April 2, 2015
The popularity of benzodiazepines, their advantages, and inadequate pharmacological alternatives-replyMark Olfson, Marissa King, Michael Schoenbaum
Pageof 69